In conclusion, the results of the present study suggest that the cholangiocarcinoma (CHOL)-hub genes (SNX15, ATP2A1, PDCD10, BET1, and HMGA2) can be used as biomarkers of tumor progression, metastasis, therapy outcome, and poor prognoses of CHOL. This evidence concerns the gene ATP2A1 and cholangiocarcinoma.